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We read with great interest the paper of Chen and colleagues.1 
It highlights the practical role of nasal cytology (NC) in the man-
agement of allergic rhinitis (AR) in clinical practice.1 We would 
like to stimulate debate about this matter, reporting our experi-
ence in allergen immunotherapy (AIT) prescription. In this re-
gard, house dust mites (HDMs) commonly cause AR, mainly in 
children, and AIT is the unique causal treatment.2 Although 
AIT has long duration, expensive cost, and sometimes limited 
efficacy, there is the need to well define the characteristics of 
ideal eligible candidates for HDM-AIT as recently appointed.3 
On the other hand, AR may frequently be associated with other 
upper airway disorders, including nonallergic rhinitis (NAR). 
NAR presents symptoms caused by non-immunoglobulin E 
(IgE)-mediated pathogenesis. Different types of NAR may exist 
and NAR classification is based on NC assessment providing 
predominant infiltrating cells: eosinophils (NARES), mast cells 
(NARMA), both (NARESMA), and neutrophils (NARNE).4 In 
this context, an Italian multicenter observational survey (con-
ducted in 17 allergy clinics) investigated the role of NC in the 
workup of AR patients with HDM allergy. Inclusion criteria were: 
age between 6 and 60 years, diagnosis of AR, monoallergy to 
HDMs, and written informed consent. AR diagnosis was estab-
lished according to validated criteria, such as consistency be-
tween symptoms occurrence after exposure to dust and docu-
mented sensitization to HDMs. Exclusion criteria were: a differ-
ent age, allergy to other allergens, a previous history of AIT, and 
severe psychiatric disorders. The study was approved by the 
Ethical Committee of each participating allergy center (approv-
al No. 2233). The study was managed, monitored, and analyzed 
by a Contract Research Organization (CD-Pharma Group, Mi-
lan, Italy) using electronic case report forms. Stallergenes Italia 
(Milan, Italy) sponsored the study. Nasal endoscopy and NC 
were performed as previously reported.4
Forty-six patients with AR to HDMs (24 females and 22 males; 
mean age 21 years, age range 6-56 years) were evaluated. NC 
assessment showed that 21 AR patients (45.7%) presented also 
NAR as represented in Figure A. In detail, 11 patients had 
NARE SMA, 6 NARNE, 3 NARMA, and 1 NARES as reported in 
Figure B. The present finding is clinically relevant as it under-
lines the high prevalence of associated NAR in patients with 
HDM-AR (about 50%). The importance of this outcome has 
clinical impact as patients with NAR, mainly NARESMA, usual-
ly show more severe symptoms and resistance to antihista-
mines.5 On the other hand, AIT is usually prescribed, regardless 
of NAR evidence in clinical practice.6,7 At present, nasal comor-
bidity is not considered an obstacle to AIT prescription, even 
though this issue should be adequately considered in clinical 
practice. In this regard, AIT should be prescribed after a thor-
ough assessment to define eligible candidates as previously dis-
cussed.7
In conclusion, the current findings derived from a real world 
multi-center study demonstrate that NAR may frequently be as-
sociated with AR, so from a pragmatic point of view NC should 
routinely be assessed in the workup of patients with AR to HDMs.
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Figure. (A) Distribution expressed as percentage of patients with or without associated NAR. (B) Distribution expressed as percentage of patients with NARESMA 
(n=11), NARNE (n=6), NARMA (n=3), and NARES (n=1). NAR, nonallergic rhinitis; NARESMA, nonallergic rhinitis with eosinophils and mast cells; NARNE, nonal-
lergic rhinitis with neutrophils; NARMA, nonallergic rhinitis with mast cells; NARES, nonallergic rhinitis with eosinophils.
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